KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EPS (Basic) (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EPS (Basic) for 17 consecutive years, with $0.54 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 980.0% to $0.54 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.47, a 178.68% increase, with the full-year FY2025 number at $3.47, up 178.68% from a year prior.
  • EPS (Basic) was $0.54 for Q4 2025 at Bristol Myers Squibb, down from $1.08 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.21 in Q1 2025 to a low of -$5.89 in Q1 2024.
  • A 5-year average of $0.45 and a median of $0.79 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): surged 1275.0% in 2021, then tumbled 645.37% in 2024.
  • Bristol Myers Squibb's EPS (Basic) stood at $1.07 in 2021, then fell by 10.28% to $0.96 in 2022, then dropped by 9.38% to $0.87 in 2023, then plummeted by 94.25% to $0.05 in 2024, then skyrocketed by 980.0% to $0.54 in 2025.
  • Per Business Quant, the three most recent readings for BMY's EPS (Basic) are $0.54 (Q4 2025), $1.08 (Q3 2025), and $0.64 (Q2 2025).